2 completed, 1 recruiting. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Recruiting 1 |
| Phase 2 | 2 | Completed 1, Recruiting 1 |
Follow Spago Nanomedical AB: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer [177Lu]Lu-SN201 - Solid Tumor, Metastatic Cancer | Phase 1 / Phase 2 | Recruiting | Spago Nanomedical AB | 90 | 2023-12-06 | 2025-11-20 |
| Efficacy of SN132D in Patients With Suspected Endometriosis SN132D - Endometriosis | Phase 2 | Completed | Spago Nanomedical AB | 8 | 2022-11-17 | 2023-12-12 |
| A First-in-human Clinical Evaluation of SN132D in Patients With Breast and Pancreatic Cancer SN132D - Breast Cancer, Pancreas Cancer | Phase 1 | Completed | Spago Nanomedical AB | 14 | 2019-08-23 | 2022-12-09 |
Breast Neoplasms (1) · Endometriosis (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Pancreatic Neoplasms (1)
Sweden (2) · Australia (1)
Dan Curiac, MD, PhD (1) · Kim Taubman (1) · Ligita Jokubkiene, MD, PhD (1)
2018 (1)